Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

167
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
167
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

147
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
147
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

127
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
127

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Developing a Clinically Practical Biomaterial Platform for Endogenous Liver Regeneration.

Gels (Basel, Switzerland)·2026
Same author

Ruptured Subclavian Artery Pseudoaneurysm Following Percutaneous Transesophageal Gastrostomy Tube Placement.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Investigating the Causes of an Extinction Catastrophe: Controlling Introduced Predators Remains Essential for Conserving Australia's Mammals.

Bioscience·2026
Same author

Pulmonary Arteriovenous Fistula Embolization in Epithelioid Trophoblastic Tumor Metastasis.

Journal of vascular and interventional radiology : JVIR·2026
Same author

Intravascular Ultrasound Enhances Diagnostic Yield and Interventional Decision-Making in Upper Extremity and Thoracic Veno-Occlusive Disease.

Cardiovascular and interventional radiology·2026
Same author

Erratum: Interventional Radiology Management of Vascular Trauma in the Pelvis: Literature, Current Practice, and Strategies for the Future.

Seminars in interventional radiology·2025
Same journal

Orbital Imaging.

Radiologic clinics of North America·2026
Same journal

Imaging, Management, and Treatment of Orbital Trauma.

Radiologic clinics of North America·2026
Same journal

Imaging Findings after Multidisciplinary Treatment for Orbital and Ocular Adnexal Cancers.

Radiologic clinics of North America·2026
Same journal

Orbital Tumors: What the Radiologist Needs to Know from the Orbital Surgeon's Perspective.

Radiologic clinics of North America·2026
Same journal

Multidisciplinary Management of Tumors of the Orbit.

Radiologic clinics of North America·2026
Same journal

Skull Base, Bone, Pituitary-Regions around Orbit that Affect Vision.

Radiologic clinics of North America·2026
查看所有相关文章

相关实验视频

Updated: May 30, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.1K

肺血管干预 肺血管干预

Grace Laidlaw1, Hugh McGregor1, Karim Valji1

  • 1Section of Interventional Radiology, Department of Radiology, University of Washington, Box 357233, 1959 Northeast Pacific Street, Seattle, WA 98195, USA.

Radiologic clinics of North America
|January 25, 2025
PubMed
概括
此摘要是机器生成的。

血管内干预为各种肺血管疾病 (如血栓和形) 提供安全有效的方法. 这一审查提高了操作人员对这些关键程序的理解,以获得更好的患者结果.

关键词:
血栓形成的过程中发生了栓塞.血管内脏的内血管.血栓溶解 (Hemoptysis) 是一种血液溶解的方法.形状不良的形.肺部 肺部 肺部 肺部血栓塞栓症 血栓塞栓症 血栓塞栓症

更多相关视频

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

12.2K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.1K

相关实验视频

Last Updated: May 30, 2025

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets
08:08

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

14.1K
Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet
09:22

Chronic Thromboembolic Pulmonary Hypertension and Assessment of Right Ventricular Function in the Piglet

Published on: November 4, 2015

12.2K
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
08:34

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

7.1K

科学领域:

  • 心脏病学 心脏病学
  • 干预性放射学 干预性放射学
  • 肺部医学 肺部医学

背景情况:

  • 肺血管病理包括一系列需要专门管理的疾病.
  • 内血管技术已经成为一种关键的治疗方式.

研究的目的:

  • 审查常见的肺血管病理的内血管管理的指示,禁忌,技术和结果.
  • 提高操作员对这些干预程序的熟悉和熟练程度.

主要方法:

  • 审查当前的文献和在肺血管疾病的内血管治疗中建立的实践.
  • 对各种病理的病例研究和程序结果的分析.

主要成果:

  • 血管内干预已被证明是急性/慢性血栓栓塞性疾病,肺动脉静脉形形 (pAVMs),出血和异物检索的安全有效治疗方法.
  • 已建立的协议和技术在各种肺血管疾病中带来了有利的结果.

结论:

  • 血管内干预是管理多种肺血管疾病的多功能和有效策略.
  • 提高操作员对这些技术的熟悉度是优化患者护理和治疗成功的关键.